What do systematic reviews say?

Budesonide vs placebo

It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.43, 2.17]
  5 studies · 290 participants
  Very low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.09 [0.01, 1.65]
  1 study · 55 participants
  Low

Budesonide 9 mg vs steroids

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.57 [0.18, 1.84]
  5 studies · 522 participants
  Low

Budesonide 3 mg vs placebo

Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.66 [0.11, 3.8]
  1 study · 133 participants
  Low

Budesonide 9 mg vs mesalamine

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.43 [0.18, 1.03]
  2 studies · 489 participants
  Low

Budesonide 9 mg vs placebo

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.14 [0.46, 2.79]
  3 studies · 379 participants
  Low

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.55 [0.45, 5.34]
  2 studies · 181 participants
  Low

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.1 [0.55, 2.22]
  2 studies · 512 participants
  Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.94 [0.56, 1.58]
  1 study · 254 participants
  Moderate

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Oral viscous budesonide vs swallowed fluticasone

Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.98 [0.42, 2.32]
  1 study · 129 participants
  Low